Rapamycin prolongs susceptibility of responding T cells to tolerance induction by CD8+ veto cells

Transplantation

Volumn 81, Issue 1, 2006, Pages 88-94

  Anderson, Kimberly M ^a   Zimring, James C ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Rapamycin; Tolerance; Veto cells

Indexed keywords

ANTIGEN; CD8 ANTIGEN; CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT; RAPAMYCIN; T LYMPHOCYTE RECEPTOR;

ADOPTIVE IMMUNOTHERAPY; ANIMAL CELL; APOPTOSIS; ARTICLE; CELL ACTIVITY; CELL DIFFERENTIATION; CELL TYPE; CONTROLLED STUDY; CYTOLYSIS; FEMALE; HYPOTHESIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; TRANSGENIC MOUSE;

ANIMALS; ANTIBODIES; ANTIGENS, CD8; ANTIGENS, CD95; APOPTOSIS; CELL LINE; CYCLOSPORINE; FEMALE; IMMUNE TOLERANCE; IMMUNOSUPPRESSIVE AGENTS; LYMPHOCYTE DEPLETION; MICE; MICE, INBRED BALB C; SIROLIMUS; T-LYMPHOCYTES; TIME FACTORS;

EID: 31044446127     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.tp.0000185302.38890.6b     Document Type: Article

References (25)

1. Krensky AM, Strom TB, Bluestone JA. The Pharmacological Basis of Therapeutics. 10th ed. New York: McGraw-Hill, 2001.
2. Snydman DR. Infection in solid organ transplantation. Transpl Infect. Dis 1999; 1 (1): 21.
3. Thomas JM, Verbanac KM, Carver FM, et al. Veto cells in transplantation tolerance. Clin Transpl 1994;8 (2 Pt 2):195.
4. Fink PJ, Shimonkevitz RP, Bevan MJ. Veto cells. Annu Rev Immunol 1988; 6: 115.
5. George JF, Thomas JM. The molecular mechanisms of veto mediated regulation of alloresponsiveness. J Mol Med 1999; 77 (7): 519.
6. Miller RG, Muraoka S, Claesson MH, et al. The veto phenomenon in T-cell regulation. Ann NY Acad Sci 1988; 532: 170.
7. Reich-Zeliger S, Zhao Y, Krauthgamer R, et al. Anti-third party CD8+ CTLs as potent veto cells: coexpression of CD8 and FasL is a prerequisite. Immunity 2000; 13 (4): 507.
8. Thomas JM, Carver FM, Cunningham PR, et al. Kidney allograff tolerance in primates without chronic immunosuppression-the role of veto cells. Transplantation 1991; 51 (1): 198.
9. Thomas Carver FM, Cunningham P, et al. Veto cells induce long-term kidney allograft tolerance in primates without chronic immunosuppression. Transplant. Proc 1991; 23 (1 Pt 1):11.
10. Bachar-Lustig E, Reich-Zeliger S, Reisner Y. Anti-third-party veto CTLs overcome rejection of hematopoietic allografts: synergism with rapamycin and BM cell dose. Blood 2003; 102 (6): 1943.
11. Gur H, Krauthgamer R, Berrebi A, et al. Tolerance induction by megadose hematopoietic progenitor cells: expansion of veto cells by short-term culture of purified human CD34(+) cells. Blood 2002; 99 (11): 4174.
12. Reisner Y, Martelli MF. Transplantation tolerance induced by "mega dose" CD34+ cell transplants. Exp Hematol 2000; 28 (2): 119.
13. Muraoka S, Ehman DL, Miller RG. Irreversible inactivation of activated cytotoxic T lymphocyte precursor cells by "anti-self" suppressor cells present in murine bone marrow T cell colonies. Eur J Immunol 1984; 14 (11): 1010.
14. Claesson MH, Miller RG. Functional heterogeneity in allospecific cytotoxic T lymphocyte clones. ICTL clones express strong anti-self suppressive activity. J Exp Med 1984; 160 (6): 1702.
15. Zimring JC, Chadwick TE, Hillyer CD, Roback JD. Effect of mediators of innate immunity and inflammation on CD8+ veto cells. Transplantation 2004; 78 (11): 1597.
16. Lichtenfels R, Biddison WE, Schulz H, et al. CARE-LASS (calcein-release-assay), an improved fluorescence-based test system to measure cytotoxic T lymphocyte activity. J Immunol Meth 1994; 172 (2): 227.
17. Sha WC, Nelson CA, Newberry RD, et al. Selective expression of an antigen receptor on CD8-bearing T lymphocytes in transgenic mice. Nature 1988; 335 (6187): 271.
18. Rubocki RJ, Hansen TH, Lee DR. Molecular studies of murine mutant BALB/c-H-2dm2 define a deletion of several class I genes including the entire H-2Ld gene. Proc Natl Acad Sci USA 1986; 83 (24): 9606.
19. Robinson PJ. Synthesis of a defective H-2 histocompatibility antigen by mutant mouse strain BALB/c-H-2dm2. Immunogenetics 1982; 15 (4): 333.
20. Kranz DM, Sherman DH, Sitkovsky MV, et al. Immunoprecipitation of cell surface structures of cloned cytotoxic T lymphocytes by clone-specific antisera. Proc Natl Acad Sci USA 1984; 81 (2): 573.
21. Vermes I, Haanen C, Steffens-Nakken H, Reutelingsperger C. A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V. J Immunol Meth 1995; 184 (1): 39.
22. Wyllie AH. Glucocorticoid-induced thymocyte apoptosis is associated with endogenous endonuclease activation. Nature 1980; 284 (5756): 555.
23. Cohen JJ, Duke RC. Glucocorticoid activation of a calcium-dependent endonuclease in thymocyte nuclei leads to cell death. J Immunol 1984; 132 (1): 38.
24. Hiruma K, Gress RE. Cyclosporine A and peripheral tolerance. Inhibition of veto cell-mediated clonal deletion of postthymic precursor cytotoxic T lymphocytes. J Immunol 1992; 149 (5): 1539.
25. Chrobak P, Gress RE. Veto activity of activated bone marrow does not require perform and Fas ligand. Cell Immunol 2001; 208 (2): 80.